About me
About me
Australian Society for Microbiology, Australian Society for Antimicrobials, Australian Society for Biochemistry and Molecular Biology, Adelaide Protein Group, American Society for Microbiology, Member of the Institutional Biosafety Committee.
My research focuses on antimicrobial resistance. ‘Superbugs’ are costing the medical and veterinary industry billions of dollars a year and antimicrobial resistance is one of the world’s most pressing health problems. According to the WHO we are fast approaching a post-antibiotic era where small injuries and minor infections will once again be fatal. Work in my laboratory is aimed at finding novel ways of treating infectious disease by characterising bacterial membrane proteins that are involved in drug resistance and/or virulence and on developing drugs that act on these targets. We are currently working on drug efflux pumps, iron transporters and cell division proteins in pathogenic bacteria. Most of our work... Read more
Research
Excludes commercial-in-confidence projects.
Turning antimicrobial resistance in residential aged care inside-out from the patient to facility level, MRFF - Targeted Call for Research - Antimicrobial Resistance, 26/06/2018 - 31/05/2023
Reversing antibiotic resistance with efflux pump inhibitors, NHMRC - Project Grant, 01/01/2018 - 31/12/2021
Improving safety of vegetable produce through on‐farm sanitation, using Electrolysed Oxidising (EO) Water - VG15068, Hort Innovation, 01/06/2017 - 31/05/2020
Research Infrastructure Fund (RIF) Grant 2016 Round 2 - Biofilm Testing Facility, Adelaide Integrated Bioscience Laboratories, 28/11/2016 - 31/12/2017
Investigation of new anti-bacterials from Australian medicinal plants, James N Kirby Foundation, 01/07/2014 - 30/09/2015
We run an antimicrobial screening facility where we screen natural and synthetic compounds for antimicrobial activity, antibiofilm activity and the reversal of resistance.
Research
Research outputs for the last seven years are shown below. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2015 |
Open access
143
136
2
|
2014 |
Open access
52
48
3
|
Year | Output |
---|---|
2020 |
2
|
2013 |
|
2008 |
6
|
Year | Output |
---|---|
2022 |
|
2022 |
Open access
1
|
2021 |
Open access
1
2
1
|
2021 |
Open access
73
|
2021 |
2
2
|
2021 |
3
3
1
|
2021 |
2
2
1
|
2021 |
Open access
6
|
2021 |
Open access
2
2
1
|
2021 |
3
2
1
|
2021 |
Open access
2
4
1
|
2021 |
Open access
2
2
1
|
2021 |
Open access
12
10
7
|
2020 |
Open access
23
24
1
|
2020 |
Open access
5
5
2
|
2020 |
2
3
|
2020 |
3
3
2
|
2020 |
3
2
1
|
2020 |
3
2
|
2020 |
Open access
7
7
4
|
2020 |
7
8
|
2020 |
7
7
1
|
2019 |
Open access
13
14
|
2019 |
1
|
2019 |
Open access
5
5
|
2019 |
Open access
10
11
4
|
2019 |
Open access
9
8
1
|
2019 |
Open access
11
11
1
|
2019 |
Open access
23
25
3
|
2018 |
18
18
1
|
2018 |
20
20
1
|
2018 |
Open access
17
16
1
|
2018 |
16
17
|
2018 |
Open access
17
14
1
|
2018 |
Open access
16
18
3
|
2018 |
20
19
|
2017 |
75
78
38
|
2017 |
25
23
|
2017 |
Open access
20
16
2
|
2017 |
13
14
|
2017 |
31
30
|
2017 |
Open access
26
25
1
|
2017 |
Open access
62
50
1
|
2017 |
Open access
19
17
|
2016 |
Open access
8
3
3
|
2016 |
Open access
18
16
3
|
2016 |
64
62
|
2016 |
7
8
3
|
2015 |
Open access
143
136
2
|
2014 |
Open access
366
361
10
|
2014 |
Open access
52
48
3
|
2014 |
15
14
|
2012 |
Open access
23
23
|
2010 |
Open access
38
36
|
2009 |
Open access
140
120
|
2009 |
Open access
29
|
2008 |
40
38
|
Research
My research focuses on antimicrobial resistance. ‘Superbugs’ are costing the medical and veterinary industry billions of dollars a year and antimicrobial resistance is one of the world’s most pressing health problems. According to the WHO we are fast approaching a post-antibiotic era where small injuries and minor infections will once again be fatal. Work in my laboratory is aimed at finding novel ways of treating infectious disease by characterising bacterial membrane proteins that are involved in drug resistance and/or virulence and on developing drugs that act on these targets. We are currently working on drug efflux pumps, iron transporters and cell division proteins in pathogenic bacteria. Most of our work focusses on the Gram-negative pathogen P. aeruginosa. This pathogen is associated with a range of life-threatening nosocomial infections and is the main cause of mortality in patients with cystic fibrosis. P. aeruginosa infections are hard to treat since this organism displays resistance against multiple classes of antimicrobials. Central to this bacterium’s high intrinsic drug resistance is the expression of drug efflux pumps and its ability to form antibiotic-tolerant biofilms.
External engagement & recognition
Organisation | Country |
---|---|
Advanced Veterinary Therapeutics | AUSTRALIA |
Ardabil University of Medical Sciences | IRAN |
Baylor College of Medicine | UNITED STATES |
CRC Care | AUSTRALIA |
Deakin University | AUSTRALIA |
Ecas4 Australia | AUSTRALIA |
ECAS4 Australia | AUSTRALIA |
Ecas4 Australia Pty Ltd | AUSTRALIA |
Ecas4 Pty Ltd | AUSTRALIA |
Elizabeth Macarthur Agricultural Institute | AUSTRALIA |
Flinders University | AUSTRALIA |
Ghent University | BELGIUM |
Goethe University Frankfurt | GERMANY |
Liaocheng University | CHINA |
Luoda Pharma | AUSTRALIA |
Luoda Pharma Pty Ltd | AUSTRALIA |
Macquarie University | AUSTRALIA |
Microbial Screening Technologies Pty Ltd | AUSTRALIA |
Micromyx | UNITED STATES |
Monash University | AUSTRALIA |
Murdoch University | AUSTRALIA |
Neoculi Pty Ltd | AUSTRALIA |
Neoculi Pty. Ltd. | AUSTRALIA |
Northern Technical University | IRAQ |
Pontifical Catholic University of Chile | CHILE |
Qingdao University | CHINA |
Queen Elizabeth Hospital | AUSTRALIA |
Queensland Department of Agriculture and Fisheries | AUSTRALIA |
ReaLi Tide Biological Technology | CHINA |
ReaLi Tide Biological Technology (Weihai) Co. Ltd | CHINA |
Sao Paulo State University | BRAZIL |
Shandong Center for Disease Control and Prevention | CHINA |
Shandong University | CHINA |
South Australian Research and Development Institute (SARDI) | AUSTRALIA |
South East Vets | UNITED STATES |
Universidade Sao Francisco | BRAZIL |
University of Adelaide | AUSTRALIA |
University of Cambridge | UNITED KINGDOM |
University of Copenhagen | DENMARK |
University of Durham | UNITED KINGDOM |
University of Newcastle | AUSTRALIA |
University of Oxford | UNITED KINGDOM |
University of Queensland | AUSTRALIA |
University of San Francisco | UNITED STATES |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
University of Technology Sydney | AUSTRALIA |
Vietnam National University of Agriculture | VIET NAM |
Zaozhuang University | CHINA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Editorial Board Member ('Antimicrobials, Resistance and Chemotherapy')Frontiers in Microbiology |
2017 |
Guest Editor for a special issueEssays in Biochemistry |
2017 |
MemberThe Australian Society for Microbiology |
2017 |
MemberAustralian Society for Antimicrobials |
2017 |
MemberAustralian Society for Biochemistry and Molecular Biology (ASBMB) |
2017 |
MemberAdelaide Protein Group, Australian Society for Biochemistry and Molecular Biology (ASBMB) |
2017 |
MemberAmerican Society for Microbiology |
2017 |
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
Antimicrobial resistance and antimicrobial drug development | Current |
Antimicrobial resistance profiles and mechanisms of resistance in bacteria isolated from healthcare settings. | Current |
Characterisation and potential new treatments of colistin resistant Chryseobacterium spp.isolated from healthcare facilities | Current |
Risk factors in the development and dissemination of antimicrobial resistance in residential age care facilities | Current |
The effect of hospital effluent on the antimicrobial resistance ecology of waste water. | Current |
Understanding resistance in critically important pathogens as a basis for antimicrobial drug discovery | Current |
A combined in silico and microbiological approach for the identification of novel efflux pump inhibitors against AcrAB-TolC | Completed |
Characterisation of antimicrobial resistance in Pseudomonas aeruginosa and Escherichia coli from clinical and environmental settings | Completed |
Inhibitors of efflux to reverse resistance in Escherichia coli | Completed |
Investigation of the activity of a caspofungin-grafted surface coating on attaching pathogenic fungi | Completed |
Reversing multi-drug resistance with efflux pump inhibitors | Completed |
Targeting bacterial cellular division via FtsZ as an approach in the development of new antimicrobial agents | Completed |